Fall Skin Care Sale

Life Extension Magazine

Life Extension Magazine February 2014
Report  

Brain Tumor Treatment Breakthrough!

By William Faloon and Lisa Antone

Summary

Recent research has established a surprising connection between a common virus, CMV, and a deadly brain tumor, glioblastoma. This relationship opens the door to a variety of forms of treatment and prevention of brain and other cancers.

At present, even with chemotherapy, survival in glioblastoma patients is rarely more than 15 months after diagnosis.42

But CMV proteins and DNA are found in the vast majority of glioblastomas removed at surgery, and the amount of CMV has been found to correlate closely with the severity of the tumor.1,2,22,45 This suggests that anti-CMV treatment might ameliorate glioblastoma and improve prognosis.

Indeed, treatment with valganciclovir, a specific anti-CMV drug, has been shown to dramatically increase overall survival in two studies of glioblastoma patients—as much as quadrupling life span!1,49

However, for those with the CMV virus, but without glioblastoma, there are a few supplements that may help fight CMV infection and can mitigate its impact on your body.51-58

You should consider being tested for CMV, by means of a blood test described in the sidebar on page 2. If you test positive, then start some of the recommendations made in this article.

The comforting news for Life Extension® members is that they have been supplementing with immune boosting nutrients for many decades.

If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027.

References

  1. Soderberg-Naucler C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. NEJM. Sep 5 2013;369(10):985-6.
  2. Dziurzynski K, Chang SM, Heimberger AB, et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. Mar 2012;14(3):246-55.
  3. Barami K. Oncomodulatory mechanisms of human cytomegalovirus in gliomas. J Clin Neurosci. Jul 2010;17(7):819-23.
  4. Soroceanu L, Cobbs CS. Is HCMV a tumor promoter? Virus Res. May 2011;157(2):193-203.
  5. Available at http://www.cdc.gov/cmv/overview.html. Accessed December 11, 2013.
  6. Tommasino M. The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol. 2013 Dec 4.
  7. Cobbs CS. Evolving evidence implicates cytomegalovirus as a promoter of malignant glioma pathogenesis. Herpesviridae. 2011 Oct 26;2(1):10.
  8. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain. 2007 Oct;130(Pt 10):2596-606.
  9. Looney RJ, Falsey A, Campbell D, et al. Role of cytomegalovirus in the T cell changes seen in elderly individuals. Clin Immunol. 1999 Feb;90(2):213-9.
  10. Pawelec G, McElhaney JE, Aiello AE, Derhovanessian E. The impact of CMV infection on survival in older humans. Curr Opin Immunol. 2012 Aug;24(4):507-11.
  11. Haeseker MB, Pijpers E, Dukers-Muijrers NH, et al. Association of cytomegalovirus and other pathogens with frailty and diabetes mellitus, but not with cardiovascular disease and mortality in psycho-geriatric patients; a prospective cohort study. Immun Ageing. 2013;10(1):30.
  12. Wang GC, Kao WH, Murakami P, et al. Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study. Am J Epidemiol. 2010 May 15;171(10):1144-52.
  13. Rizzo LB, Do Prado CH, Grassi-Oliveira R, et al. Immunosenescence is associated with human cytomegalovirus and shortened telomeres in type I bipolar disorder. Bipolar Disord. 2013 Sep 10.
  14. Turner JE, Campbell JP, Edwards KM, et al. Rudimentary signs of immunosenescence in Cytomegalovirus-seropositive healthy young adults. Age (Dordr). 2013 Jul 12.
  15. Arslan F, Batirel A, Mert A, Ozer S. Cytomegalovirus (CMV)-related cutaneous necrotizing vasculitis: case report and literature review. Braz J Infect Dis. 2012 Sep-Oct;16(5):482-5.
  16. Available at: http://www.mayoclinic.com/health/cmv/DS00938/DSECTION=symptoms. Accessed December 11, 2013.
  17. Johnson JM, Anderson BL. Cytomegalovirus: should we screen pregnant women for primary infection? Am J Perinatol. 2013 Feb;30(2):121-4.
  18. Available at: http://www.cdc.gov/cmv/overview.html. Accessed December 11, 2013.
  19. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010 Jul;20(4):202-13.
  20. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis. 2010 Jun 1;50(11):1439-47.
  21. Colugnati FA, Staras SA, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis. 2007 Jul 2;7:71.
  22. Michaelis M, Doerr HW, Cinatl J. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia. 2009 Jan;11(1):1-9.
  23. Richardson A. Is breast cancer caused by late exposure to a common virus? Med Hypotheses. 1997 Jun;48(6):491-7.
  24. Lepiller Q, Tripathy MK, Di Martino V, Kantelip B, Herbein G. Increased HCMV seroprevalence in patients with hepatocellular carcinoma. Virol J. 2011;8:485.
  25. Crough T, Beagley L, Smith C, Jones L, Walker DG, Khanna R. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol Cell Biol. 2012 Oct;90(9):872-80.
  26. Taher C, de Boniface J, Mohammad AA, et al. High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. PLoS One. 2013;8(2):e56795.
  27. Johnsen JI, Baryawno N, Söderberg-Nauclér C. Is human cytomegalovirus a target in cancer therapy? Oncotarget. 2011 Dec;2(12):1329-38.
  28. Giuliani L, Jaxmar T, Casadio C, et al. Detection of oncogenic viruses SV40, BKV, JCV, HCMV, HPV and p53 codon 72 polymorphism in lung carcinoma. Lung Cancer. 2007 Sep;57(3):273-81.
  29. Moon JS, Lee MY, Park SW, et al. Androgen-dependent activation of human cytomegalovirus major immediate-early promoter in prostate cancer cells. Prostate. 2008 Sep 15;68(13):1450-60.
  30. El-Shinawi M, Mohamed HT, El-Ghonaimy EA, et al. Human cytomegalovirus infection enhances NF-kappaB/p65 signaling in inflammatory breast cancer patients. PLoS One. 2013;8(2):e55755.
  31. Price RL, Song J, Bingmer K, et al. Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Res. 2013 Jun 1;73(11):3441-50.
  32. Matlaf LA, Harkins LE, Bezrookove V, Cobbs CS, Soroceanu L. Cytomegalovirus pp71 protein is expressed in human glioblastoma and promotes pro-angiogenic signaling by activation of stem cell factor. PLoS One. 2013;8(7):e68176.
  33. Bongers G, Maussang D, Muniz LR, et al. The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J Clin Invest. 2010 Nov;120(11):3969-78.
  34. Baryawno N, Rahbar A, Wolmer-Solberg N, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest. 2011 Oct;121(10):4043-55.
  35. El-Shinawi M, Mohamed HT, El-Ghonaimy EA, et al. Human cytomegalovirus infection enhances NF-kappaB/p65 signaling in inflammatory breast cancer patients. PLoS One. 2013;8(2):e55755.
  36. Price RL, Song J, Bingmer K, et al. Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Res. 2013 Jun 1;73(11):3441-50.
  37. Lepiller Q, Abbas W, Kumar A, Tripathy MK, Herbein G. HCMV activates the IL-6-JAK-STAT3 axis in HepG2 cells and primary human hepatocytes. PLoS One. 2013;8(3):e59591.
  38. Bai RY, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol. 2011 Sep;13(9):974-82.
  39. Le Mercier M, Hastir D, Moles Lopez X, et al. A simplified approach for the molecular classification of glioblastomas. PLoS One. 2012;7(9):e45475.
  40. Horing E, Harter PN, Seznec J, et al. The “go or grow” potential of gliomas is linked to the neuropeptide processing enzyme carboxypeptidase E and mediated by metabolic stress. Acta Neuropathol. 2012 Jul;124(1):83-97.
  41. Thumma SR, Fairbanks RK, Lamoreaux WT, et al. Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis. World J Surg Oncol. 2012;10:75.
  42. Available at: http://www.aans.org/Patient%20Information/Conditions%20and%20Treatments/Glioblastoma%20Multiforme.aspx. Accessed September 30, 2013.
  43. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013 Nov 6;310(17):1842-50.
  44. Johnson DR, Leeper HE, Uhm JH. Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis. Cancer. 2013 Jul 18.
  45. Rahbar A, Stragliotto G, Orrego A, et al. Low levels of Human Cytomegalovirus Infection in Glioblastoma multiforme associates with patient survival; -a case-control study. Herpesviridae. 2012;3:3.
  46. Rahbar A, Orrego A, Peredo I, et al. Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. J Clin Virol. 2013 May;57(1):36-42.
  47. Meije Y, Lizasoain M, Garcia-Reyne A, et al. Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review. Clin Infect Dis. 2010 Jun 15;50(12):e73-6.
  48. Okita Y, Narita Y, Miyakita Y, Ohno M, Nagai S, Shibui S. Management of cytomegalovirus infection in a patient with malignant glioma treated with temozolomide and steroids. Intern Med. 2012;51(20):2967-71.
  49. Stragliotto G, Rahbar A, Solberg NW, et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer. 2013 Sep 1;133(5):1204-13.
  50. Kalil AC, Mindru C, Botha JF, et al. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis. Liver Transpl. 2012 Dec;18(12):1440-7.
  51. Balzarini J, Neyts J, Schols D, et al. The mannose-specific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (N-acetylglucosamine)n-specific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replication in vitro. Antiviral Res. 1992 Jun;18(2):191-207.
  52. Guo NL, Lu DP, Woods GL, et al. Demonstration of the anti-viral activity of garlic extract against human cytomegalovirus in vitro. Chin Med J (Engl). 1993 Feb;106(2):93-6.
  53. Li YN, Huang F, Liu XL, et al. Allium sativum-derived allitridin inhibits Treg amplification in cytomegalovirus infection. J Med Virol. 2013 Mar;85(3):493-500.
  54. Liu ZF, Fang F, Dong YS, Li G, Zhen H. Experimental study on the prevention and treatment of murine cytomegalovirus hepatitis by using allitridin. Antiviral Res. 2004 Feb;61(2):125-8.
  55. Salem ML, Hossain MS. Protective effect of black seed oil from Nigella sativa against murine cytomegalovirus infection. Int J Immunopharmacol. 2000 Sep;22(9):729-40.
  56. Shiraki K, Yukawa T, Kurokawa M, Kageyama S. Cytomegalovirus infection and its possible treatment with herbal medicines. Nihon Rinsho. 1998 Jan;56(1):156-60.
  57. Sookkongwaree K, Geitmann M, Roengsumran S, Petsom A, Danielson UH. Inhibition of viral proteases by Zingiberaceae extracts and flavones isolated from Kaempferia parviflora. Pharmazie. 2006 Aug;61(8):717-21.
  58. Terrasson J, Xu B, Li M, et al. Activities of Z-ajoene against tumour and viral spreading in vitro. Fundam Clin Pharmacol. 2007 Jun;21(3):281-9.
  59. Candore G, Balistreri CR, Colonna-Romano G, et al. Immunosenescence and anti-immunosenescence therapies: the case of probiotics. Rejuvenation Res. 2008 Apr;11(2):425-32.
  60. Biagi E, Candela M, Fairweather-Tait S, Franceschi C, Brigidi P. Aging of the human metaorganism: the microbial counterpart. Age (Dordr). 2012 Feb;34(1):247-67.
  61. Kawase M, He F, Miyazawa K, Kubota A, Yoda K, Hiramatsu M. Orally administered heat-killed Lactobacillus gasseri TMC0356 can upregulate cell-mediated immunity in senescence-accelerated mice. FEMS Microbiol Lett. 2012 Jan;326(2):125-30.
  62. Gill HS, Rutherfurd KJ, Cross ML. Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes. J Clin Immunol. 2001 Jul;21(4):264-71.
  63. Mane J, Pedrosa E, Loren V, et al. A mixture of Lactobacillus plantarum CECT 7315 and CECT 7316 enhances systemic immunity in elderly subjects. A dose-response, double-blind, placebo-controlled, randomized pilot trial. Nutr Hosp. 2011 Jan-Feb;26(1):228-35.
  64. Jirillo E, Jirillo F, Magrone T. Healthy effects exerted by prebiotics, probiotics, and symbiotics with special reference to their impact on the immune system. Int J Vitam Nutr Res. 2012 Jun;82(3):200-8.
  65. Haase H, Mocchegiani E, Rink L. Correlation between zinc status and immune function in the elderly. Biogerontology. 2006 Oct-Dec;7(5-6):421-8.
  66. Putics A, Vodros D, Malavolta M, Mocchegiani E, Csermely P, Soti C. Zinc supplementation boosts the stress response in the elderly: Hsp70 status is linked to zinc availability in peripheral lymphocytes. Exp Gerontol. 2008 May;43(5):452-61.
  67. Varin A, Larbi A, Dedoussis GV, et al. In vitro and in vivo effects of zinc on cytokine signalling in human T cells. Exp Gerontol. 2008 May;43(5):472-82.
  68. Guayerbas N, Puerto M, Ferrandez MD, De La Fuente M. A diet supplemented with thiolic anti-oxidants improves leucocyte function in two strains of prematurely ageing mice. Clin Exp Pharmacol Physiol. 2002 Nov;29(11):1009-14.
  69. De la Fuente M. Murine models of premature ageing for the study of diet-induced immune changes: improvement of leucocyte functions in two strains of old prematurely ageing mice by dietary supplementation with sulphur-containing antioxidants. Proc Nutr Soc. 2010 Nov;69(4):651-9.
  70. Khan Z, Bhadouria P, Bisen PS. Nutritional and therapeutic potential of Spirulina. Curr Pharm Biotechnol. 2005 Oct;6(5):373-9.
  71. Blinkova LP, Gorobets OB, Baturo AP. Biological activity of Spirulina. Zh Mikrobiol Epidemiol Immunobiol. 2001 Mar-Apr (2):114-8.
  72. Selmi C, Leung PS, Fischer L, et al. The effects of Spirulina on anemia and immune function in senior citizens. Cell Mol Immunol. 2011 May;8(3):248-54.
  73. Kast RE, Karpel-Massler G, Halatsch ME. Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin? Br J Pharmacol. 2011 Nov;164(5):1393-6.
  74. Soritau O, Tomuleasa C, Aldea M, et al. Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas. J buon. 2011 Apr-Jun;16(2):282-9.
  75. Ferla R, Haspinger E, Surmacz E. Metformin inhibits leptin-induced growth and migration of glioblastoma cells. Oncol Lett. 2012 Nov;4(5):1077-81.
  76. Sato A, Sunayama J, Okada M, et al. Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Transl Med. 2012 Nov;1(11):811-24.
  77. Available at: http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/62067. Accessed December 12, 2013.
  78. Carlson A, Norwitz ER, Stiller RJ. Cytomegalovirus infection in pregnancy: should all women be screened? Rev Obstet Gynecol. 2010 Fall;3(4):172-9.